For generations, a treatable disease has gone largely untreated across sub-Saharan Africa — not for lack of a drug, but for fear of it. A decade-long study across four African nations has now answered that fear with evidence: hydroxyurea, long standard in wealthy countries for sickle cell anaemia, does not increase infection risk in children living in resource-limited settings, and in fact appears to reduce it. The findings, drawn from over 5,000 patient-years of observation, reframe a medical caution that has quietly shaped the lives — and shortened them — for hundreds of thousands of childre
Hydroxyurea safely treats sickle cell in African children without infection risk
Approximately 550,000 children are born annually with sickle cell anaemia, predominantly in sub-Saharan Africa, experiencing pain, infections, and chronic illness without effective treatment access.
Infection rates fell as doses increased, contradicting the central fear
Mark
So this study is saying hydroxyurea is safe in Africa. But wasn't it already known to be safe in rich countries?
Mimi
Yes, but doctors were genuinely worried about using it in low-income settings. The drug suppresses immune cells, and in places where you can't easily get to a hospital, that seemed dangerous.
Luke
Right, but I want to be clear about what the study actually measured. Most infections were reported retrospectively through clinical history, not through real-time testing. So they're capturing what parents and clinicians remembered and reported, not necessarily every infection that occurred.
Mimi
That's fair. But even with that limitation, they followed 606 children for over a decade across four countries. That's substantial evidence.
Mark
And the infection rates went down, not up?
Mimi
Yes. Malaria dropped 51 percent, other infections dropped 38 percent. The opposite of what people feared.
Luke
Which is interesting, but we should ask why. The study doesn't explain the mechanism. Is it that hydroxyurea is actually protective? Or is it that healthier children—with fewer sickle crises—are simply less vulnerable to infection?
Mark
Does it matter for the practical question of whether to prescribe it?
Luke
Not really. If the drug works and doesn't cause harm, doctors should use it. But understanding why matters for future research and for knowing what to watch for in different populations.
Mimi
The study authors are recommending it as standard care now. That's a significant shift in practice.
Mark
For how many children?
nMimi: About 550,000 are born with sickle cell every year, mostly in sub-Saharan Africa. Most of them currently have no access to hydroxyurea at all.
Der Puls
- Each year, roughly 550,000 children are born with sickle cell anaemia in sub-Saharan Africa, where pain, chronic illness, and deadly infections define the disease's course — and where effective treatment has remained largely out of reach.
- Doctors long withheld hydroxyurea in low-income settings, fearing that its suppression of infection-fighting white blood cells would prove catastrophic in places where clinics are distant and antibiotics scarce.
- The REACH trial enrolled 606 children across Angola, DR Congo, Kenya, and Uganda, tracking them over more than a decade to generate the largest long-term safety dataset for hydroxyurea use in Africa.
- Rather than worsening infections, hydroxyurea cut malaria rates by 51% and non-malarial infections by 38%, with no increase in illness or death even at maximum tolerated doses.
- Researchers now call for hydroxyurea to become standard care across resource-limited settings — but the harder question is whether fragile health systems and supply chains can translate that recommendation into reality.
For generations, a treatable disease has gone largely untreated across sub-Saharan Africa — not for lack of a drug, but for fear of it. A decade-long study across four African nations has now answered that fear with evidence: hydroxyurea, long standard in wealthy countries for sickle cell anaemia, does not increase infection risk in children living in resource-limited settings, and in fact appears to reduce it. The findings, drawn from over 5,000 patient-years of observation, reframe a medical caution that has quietly shaped the lives — and shortened them — for hundreds of thousands of children born each year into the world's highest-burden region for this disease.
For more than a decade, researchers watched children in four African countries take a daily pill and live longer, healthier lives. The pill is hydroxyurea — long standard for sickle cell anaemia in wealthy nations, but viewed with deep suspicion elsewhere. A major study published in The Lancet Haematology has now dismantled the central fear that kept doctors from prescribing it: that the drug, by dampening immune function, would leave children dangerously exposed to infection in places where hospitals are scarce.
Sickle cell anaemia is overwhelmingly an African disease. Roughly 80 percent of global cases occur in sub-Saharan Africa, where some 550,000 children are born with the condition each year. Hydroxyurea works by prompting the body to produce fetal haemoglobin, which prevents red blood cells from taking the sickle shape that clogs vessels and drives the disease's worst complications. In high-income countries, it has been transformative. But the drug reduces neutrophils — white blood cells that fight infection — and in settings where a feverish child might be hours from a clinic, that trade-off seemed too dangerous.
The REACH trial was built to test that assumption. Researchers recruited 606 children aged one to ten across Angola, the Democratic Republic of Congo, Kenya, and Uganda, beginning in 2014. After an initial fixed dose, children were escalated to the maximum each could tolerate, and followed every few months over more than a decade — accumulating over 5,000 patient-years of safety data.
What emerged contradicted the prevailing caution entirely. As doses increased, infection rates fell. Malaria dropped by 51 percent; non-malarial infections by 38 percent. No increase in illness or death appeared at any dose level. Lead investigator Tom Williams of Imperial College London noted the breadth of the evidence, while senior author Russell Ware called it long-awaited confirmation of the drug's safety at maximum tolerated doses in low-income settings.
Hydroxyurea has already been shown to reduce pain crises, organ damage, and stroke risk in sickle cell patients. Now the infection fear has been answered. Researchers recommend the drug at maximum tolerated dose as standard care in resource-limited settings — a shift toward possibility for hundreds of thousands of children who currently have no access to it at all. Whether the health systems and supply chains of low-income countries can make that standard real remains the open question.
For more than a decade, researchers have watched children in four African countries take a daily pill and live longer, healthier lives. The pill is hydroxyurea, a drug that has long been standard treatment for sickle cell anaemia in wealthy nations but has been viewed with deep suspicion in poorer parts of the world. Now a major study published in The Lancet Haematology has dismantled the central fear that kept doctors from prescribing it: the worry that the drug, by dampening immune function, would leave children more vulnerable to deadly infections in places where hospitals are scarce and antibiotics are hard to find.
Sickle cell anaemia is the most common severe inherited blood disorder globally, and it is overwhelmingly an African disease. Roughly 80 percent of cases occur in sub-Saharan Africa, where approximately 550,000 children are born with the condition each year. The disease causes excruciating pain, chronic weakness, and a cascade of infections—bacterial, viral, and parasitic—that can kill. Hydroxyurea works by coaxing the body to produce fetal haemoglobin, a form of the protein that normally exists only in babies in the womb. This fetal haemoglobin prevents red blood cells from taking on the characteristic sickle shape that clogs blood vessels and triggers the disease's worst complications. In high-income countries, it has been a game-changer. But in low-income settings, caution prevailed. The drug reduces neutrophils, the white blood cells that fight infection. In places where a child with fever might be hours away from a clinic, that trade-off seemed too risky.
The REACH trial—Realizing Effectiveness Across Continents with Hydroxyurea—was designed to test whether that caution was warranted. Researchers recruited 606 children aged one to ten between 2014 and 2016 at sites in Angola, the Democratic Republic of Congo, Kenya, and Uganda. The children started on a fixed dose of hydroxyurea for six months, then the dose was increased to the maximum each child could tolerate. Researchers followed them every two to three months, tracking infections through clinical history and direct observation. Over more than a decade of treatment, they accumulated more than 5,000 patient-years of safety data.
What they found contradicted the prevailing anxiety. As hydroxyurea doses increased, infection rates actually fell. Malaria infections dropped by 51 percent. Non-malarial infections fell by 38 percent. There was no increase in the incidence or severity of infections at any dose, including at the maximum tolerated dose. No signal of harm emerged. Tom Williams, the study's lead investigator at Imperial College London's Institute of Global Health Innovation, described the scale of the evidence: "In this huge study covering more than 5,000 patient years of follow-up we found no increase of illness or death from infections, even when hydroxyurea is used at the maximum tolerated dose." Russell Ware, a senior author at Cincinnati Children's Hospital Medical Center, called the findings "long-awaited data regarding the long-term safety of hydroxyurea used at maximum tolerated dose in low-income settings."
The implications are substantial. Hydroxyurea has already been shown to reduce most sickle-related complications—pain crises, organ damage, stroke risk. Now the evidence shows it does not carry the infection penalty that doctors feared. The researchers recommend that children with sickle cell anaemia in resource-limited settings should receive hydroxyurea at the maximum tolerated dose. Williams added that the results "support the wider use of hydroxyurea as standard of care." For a disease that affects hundreds of thousands of African children each year, many of whom have no access to the drug at all, this is a shift toward possibility. The question now is whether the medical systems and supply chains in low-income countries can make that standard a reality.
Bemerkenswerte Zitate
In this huge study covering more than 5,000 patient years of follow-up we found no increase of illness or death from infections, even when hydroxyurea is used at the maximum tolerated dose.— Tom Williams, Imperial College London
These findings provide long-awaited data regarding the long-term safety of hydroxyurea used at maximum tolerated dose in low-income settings. Over 10-years of treatment, the incidence and severity of infections did not increase, and in many cases, were decreased.— Russell Ware, Cincinnati Children's Hospital Medical Center
Möchten Sie die ganze Geschichte?
Das Original lesen bei EurekAlert! Science News Releases ↗
Health & Medicine